



Thomas Berg

Contact

Thomas Berg

Publications (16)

Efe C, Nilsson E, Heurgué-Berlot A, Demir N, Semela D, Kiyici M, Schiano T, Montano-Loza A, Berg T, Ozaslan E, Yoshida E, Bonder A, Marschall H, Beretta-Piccoli B, Önnérhag K, Rorsman F, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H, Eren F, Fischer J, Chayanupatkul M, Coppo C, Purnak T, Muratori L, Werner M, Muratori P, Wahlin S. Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. *J Gastroenterol Hepatol* 2020

Dietz J, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C, Buggisch P, Matschenz K, Spengler U, Mullhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, European HCV Resistance Study Group. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. *Clin Gastroenterol Hepatol* 2019

Efe C, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kiyici M, Schiano T, Montano-Loza A, Berg T, Ozaslan E, Yoshida E, Bonder A, Marschall H, Önnérhag K, Rorsman F, Muratori P, Taşçılar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Beretta-Piccoli B, Fischer J, Çalışkan A, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Wahlin S. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. *Am J Gastroenterol* 2019; 114:1101-1108.

Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour J. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. *J Hepatol* 2017; 67:876-878.

Gauthiez E, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P, Malinverni R, Heim M, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. *Liver Int* 2017; 37:1431-1445.

Wang H, Pichulik T, Mullhaupt B, Semela D, Dufour J, Bochud P, Bowie A, Kalinke U, Berg T, Weber A, Wiese M, Löffler M, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery S, Filomena A, Wolz O, Schneiderhan-Marra N, East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. *Hepatology* 2015; 62:1375-87.

Lange C, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud P, Hiroshima Liver Study Group, Mullhaupt B, Malinverni R, Heim M, Miki D, Ochi H, Nischalke H, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour J, Gorgievski-Hrisoho M, Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PloS one* 2013; 8:e64053.

Rauch A, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann J, Berg T, Bergmann S, Negro F, Telenti A, Bochud P, Swiss Hepatitis C Cohort Study, Heim M, Günthard H, Furrer H, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour J, Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010; 138:1338-45, 1345.e1-7.

Berg T, Sarrazin C, Neumann K, Zankel M, Balk H, Buggisch P, Spengler U, Gerlach T, Hinrichsen H, Rasenack J, Möller B, Klinker H, Teuber G, Weich V, Zeuzem S. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. *Hepatology (Baltimore, Md.)* 2009; 50:369-77.

Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. *European journal of gastroenterology & hepatology* 2007; 19:639-46.

Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130:1086-97.

von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005; 129:522-7.

Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, Zeuzem S. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. *Hepatology (Baltimore, Md.)* 2004; 39:1456-7; author reply 1457-8.

Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. *Hepatology (Baltimore, Md.)* 2003; 37:1359-67.

Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology (Baltimore, Md.)* 2003; 37:600-9.

Burchert A, Wöfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller M, Berg T, Gscheidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (ST1571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. *Blood* 2002; 101:259-64.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch